JP2022540922A - ソマトスタチンモジュレーターの結晶形態 - Google Patents

ソマトスタチンモジュレーターの結晶形態 Download PDF

Info

Publication number
JP2022540922A
JP2022540922A JP2022502580A JP2022502580A JP2022540922A JP 2022540922 A JP2022540922 A JP 2022540922A JP 2022502580 A JP2022502580 A JP 2022502580A JP 2022502580 A JP2022502580 A JP 2022502580A JP 2022540922 A JP2022540922 A JP 2022540922A
Authority
JP
Japan
Prior art keywords
pattern
quinolin
hydroxybenzonitrile
dimesylate
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540922A5 (enExample
Inventor
ピー． レッディ，ジャヤチャンドラ
ヂャオ，ユーシン
ミルメフラビ，マームード
マヨ，アレックス
コタ，マドゥカー
ダッシュ，ウッタム
ウメシュ ナイーク，ヴィジャヤクマール
クマール バンダール，パラヴィーン
ファン，ユワンチン
Original Assignee
クリネティックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリネティックス ファーマシューティカルズ，インク． filed Critical クリネティックス ファーマシューティカルズ，インク．
Publication of JP2022540922A publication Critical patent/JP2022540922A/ja
Publication of JP2022540922A5 publication Critical patent/JP2022540922A5/ja
Priority to JP2025106721A priority Critical patent/JP2025141974A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022502580A 2019-07-17 2020-07-15 ソマトスタチンモジュレーターの結晶形態 Pending JP2022540922A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106721A JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875285P 2019-07-17 2019-07-17
US62/875,285 2019-07-17
PCT/US2020/042119 WO2021011641A1 (en) 2019-07-17 2020-07-15 Crystalline forms of somatostatin modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106721A Division JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Publications (2)

Publication Number Publication Date
JP2022540922A true JP2022540922A (ja) 2022-09-20
JP2022540922A5 JP2022540922A5 (enExample) 2023-07-10

Family

ID=74211310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502580A Pending JP2022540922A (ja) 2019-07-17 2020-07-15 ソマトスタチンモジュレーターの結晶形態
JP2025106721A Pending JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106721A Pending JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Country Status (4)

Country Link
US (2) US12617767B2 (enExample)
EP (1) EP3999509A4 (enExample)
JP (2) JP2022540922A (enExample)
WO (1) WO2021011641A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017296392B2 (en) 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤
AU2022281327A1 (en) * 2021-05-25 2023-12-14 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of disease
KR20240132451A (ko) * 2022-01-11 2024-09-03 크리네틱스 파마슈티칼스, 인크. 카르시노이드 증후군의 치료를 위한 소마토스타틴 조절제의 용도
CA3258700A1 (en) 2022-06-10 2023-12-14 Assia Chemical Industries Ltd. SOLID FORMS OF PALTUSOTINE AND THEIR PREPARATION METHOD
AU2024242719A1 (en) 2023-03-28 2025-09-25 Crinetics Pharmaceuticals, Inc. Compositions and methods for administering paltusotine to patients with hepatic impairment
CN117263966A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 一种硼酸衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520690A (ja) * 2005-12-05 2009-05-28 ゼノポート，インコーポレーテッド レボドパプロドラッグメシラート、その組成物、およびその使用法
US20180016252A1 (en) * 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
AU2007217474A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US20090258853A1 (en) 2006-03-13 2009-10-15 Brian Eastman Somatostatin Agonists
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US9120749B2 (en) 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
WO2012162254A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
EP2715754B1 (en) 2011-05-31 2015-07-29 Linak A/S Actuator
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
HK1211289A1 (en) 2012-08-06 2016-05-20 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
AU2014306451B2 (en) 2013-08-16 2019-01-17 Duke University Substituted hydroxamic acid compounds
CA2925651A1 (en) 2013-09-30 2015-04-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CA2943643A1 (en) 2014-03-24 2015-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
HK1255074A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
DK3368534T3 (da) 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
EP3481825A1 (en) * 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
NZ757081A (en) 2017-03-16 2023-03-31 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
WO2018208987A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
EP3664778B1 (en) 2017-08-11 2022-05-25 Merck Patent GmbH Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile
EP3740475B1 (en) 2018-01-17 2022-04-20 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
TWI852944B (zh) 2018-09-18 2024-08-21 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
JP7796115B2 (ja) 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤
AU2022281327A1 (en) 2021-05-25 2023-12-14 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520690A (ja) * 2005-12-05 2009-05-28 ゼノポート，インコーポレーテッド レボドパプロドラッグメシラート、その組成物、およびその使用法
US20180016252A1 (en) * 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, vol. p.347-365, JPN6014029314, 1999, ISSN: 0005641357 *
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, JPN6014031669, 1998, ISSN: 0005641359 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005641358 *

Also Published As

Publication number Publication date
US20260234122A1 (en) 2026-08-13
EP3999509A4 (en) 2023-07-19
US20220267295A1 (en) 2022-08-25
WO2021011641A1 (en) 2021-01-21
EP3999509A1 (en) 2022-05-25
JP2025141974A (ja) 2025-09-29
US12617767B2 (en) 2026-05-05

Similar Documents

Publication Publication Date Title
JP2025141974A (ja) ソマトスタチンモジュレーターの結晶形態
JP7113900B2 (ja) ソマトスタチンモジュレーターを製造するプロセス
JP7431813B2 (ja) ソマトスタチンモジュレーターとその使用
US20080125588A1 (en) SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES
EP3334721B1 (en) Cgrp receptor antagonists
JP2024506715A (ja) ソマトスタチンモジュレーターの結晶形態
JP5493870B2 (ja) ３，８−ジアミノテトラヒドロキノリン誘導体
JP4878285B2 (ja) アポトーシス誘発作用を有するインドール誘導体
WO2017098733A1 (ja) インドール酢酸誘導体
US20170240513A1 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
US20170247336A1 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
BR112020014462B1 (pt) Compostos, composição farmacêutica, método e processo de produção de moduladores de somatostatina
HK40034713B (en) Process of making somatostatin modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220713

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624